Betmiga launched in Jordan
Amman, Jordan; January 13, 2016: Astellas Pharma Middle East, North and Sub-Saharan Africa (MENA/SSA), today announced that a new treatment for relieving symptoms of overactive bladder (OAB) is now available in Jordan. The treatment contains the active ingredient mirabegron, providing a new and alternative treatment option to conventional antimuscarinics treatment for adult patients.
OAB is a group of urinary symptoms including strong and sudden urges to urinate without prior warning and having to urinate frequently. OAB affects more than 400 million people worldwide.1 The symptoms of OAB can significantly affect an individual’s daily activities, and also impact social, family, physical and professional settings and dynamics.2 While it is a common problem, many people are hesitant to seek consultation.
Speaking to the media, Professor Abdul Naser M. Al Shunaigat, President of Jordanian Association of Urological Surgeons said:
“OAB is a very common problem that effects the elderly more often, but also men and women of any age. In Jordan, it’s ignored by many due to lack of awareness, social stigma and embarrassment. As many as 40% of people with OAB have never consulted a healthcare professional about their symptoms.3 This is an unfortunate statistic revealing that too many people are suffering despite reliable and efficient treatment options that can improve patient’s quality of life.”
Internationally renowned specialist, Professor Marcus Drake, Consultant Surgeon at the Bristol Urological Institute, United Kingdom, commented:
“Treating patients with mirabegron was studied in several controlled clinical trials in adult men and women with overactive bladder symptoms. With mirabegron, patients experienced improved symptoms and more treatment satisfaction than those treated with a placebo. The safety profile for mirabegron makes this therapy an effective oral medication for people with overactive bladder symptoms.”
Mirabegron works by stimulating the receptors in the muscle of the bladder called beta-3 receptors causing it to relax.4 This improves the storage capacity of the bladder without inhibiting bladder contraction, thereby prolonging the time between trips to the toilet for the patient.5 Dry mouth is one of the most common and bothersome side effects of antimuscarinics, and often the reason for discontinuation of treatment.6 Studies have shown that mirabegron has a low incidence of treatment-associated side effects, including dry mouth.5,7,8,9,10,11
Mr. Amr Seif, Marketing Director Astellas Pharma MENA/SSA concluded:
“Astellas is an established leader in urology. Urological health continues to be a key priority for Astellas MENA/SSA and we are very pleased to be providing healthcare professionals with an effective treatment option to better manage these OAB conditions that can have a significant impact on patients’ lives in Jordan.”
Mirabegron is now available via prescription in Jordan in 50mg packs containing 30 tablets.
1- Irwin D.E., et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011; 108(7):1132-8.
2- Brown JS et al. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6(11 Suppl):S574-579.
3- Milsom I. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87(9): 760-766.
4- Betimga Summary of Product Characteristics. Available from: http://www.medicines.org.uk/emc/medicine/27429 Accessed January 2016.
5- Tyagi P et al. Mirabegron: safety review Expert Opin. Drug Safety 2011;10.2: 287-294.
6- Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010; 105(9): 1276-82.
7- Khullar V et al. Efficacy of mirabegron in patients with and without prior anti-muscarinic therapy for overactive bladder (OAB): Post-hoc analysis of a prospective, randomised European-Australian phase III trial. EAU 2012 Poster AM12-2389
8- Khullar V., Amarenco G., Angulo J.C., et al. Efficacy and safety of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder: results from a randomized European-Australian phase 3 trial. Eur Urol 2012;
9- Nitti V., Auerbach A., Martin N., et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2012; 10.1016/j.juro.2012.10.017.
10- Van Kerrebroeck P, Barkin J, Castro-Diaz D et al. Randomised, double-blind, placebo-controlled Phase III study to assess the efficacy and safety of mirabegron 25mg and 50 mg once daily in overactive bladder (OAB). Presented at ICS 2012.
11- Chapple CR., Kaplan SK., Mitcheson D., et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month.
12- Abrams P. et al. Reviewing the ICS 2002 Terminology Report: The Ongoing Debate. Neurourol Urodyn 2006; 25: 293-294 safety and efficacy of mirabegron, a beta3-adrenoceptor agonist, in overactive bladder. Eur Urol 2012.